trial

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

NCTId NCT06225115
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 72 (actual)
Sponsored by Kynexis B.V.
Primary completion 2024-10-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
72 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2023-12-21
Primary completion
2024-10-07
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
KYN-5356

Sponsors

Kynexis B.V.Lead Sponsor
ParexelCollaborator

Investigators

1
Hakop Gevorkyan, MD, MBAPrincipal Investigator

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
72
Phase
PHASE1
Primary Completion Date
2024-10-07
Status
COMPLETED
relationships
The graph out of here
drug
KYN-5356
drug
lead_sponsor
Kynexis B.V.
company
collaborator
Parexel
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognitive Dysfunction
indication
investigator
Hakop Gevorkyan, MD, MBA
person